 | • レポートコード：MRC2303B111 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の薬物乱用治療市場規模が予測期間中に年平均7.2％上昇すると推測されています。本調査書では、薬物乱用治療の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療種類別（アルコール依存症治療、タバコ/ニコチン依存症治療、薬物乱用治療、その他）分析、流通チャネル別（病院内薬局、小売薬局、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Alkermes PLC、Abbvie Inc.、Cipla Ltd、GlaxoSmithKline PLC、Mallinckrodt LLC、Indivior PLC、Pfizer Inc. 、Sanofi SA、Teva Pharmaceutical Industries Ltd、Orexo AB 、Apotex、BioCorRx Inc.、Opiant Pharmaceuticals Inc.、 Purdue Pharma LP、Novartis AG (Sandoz)などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の薬物乱用治療市場規模：治療種類別 - アルコール依存症治療の市場規模 - タバコ/ニコチン依存症治療の市場規模 - 薬物乱用治療の市場規模 - その他薬物乱用治療の市場規模 ・世界の薬物乱用治療市場規模：流通チャネル別 - 病院内薬局の市場規模 - 小売薬局の市場規模 - その他チャネルの市場規模 ・世界の薬物乱用治療市場規模：地域別 - 北米の薬物乱用治療市場規模 アメリカの薬物乱用治療市場規模 カナダの薬物乱用治療市場規模 メキシコの薬物乱用治療市場規模 … - ヨーロッパの薬物乱用治療市場規模 ドイツの薬物乱用治療市場規模 イギリスの薬物乱用治療市場規模 フランスの薬物乱用治療市場規模 … - アジア太平洋の薬物乱用治療市場規模 中国の薬物乱用治療市場規模 日本の薬物乱用治療市場規模 インドの薬物乱用治療市場規模 … - 南米/中東の薬物乱用治療市場規模 南アフリカの薬物乱用治療市場規模 ブラジルの薬物乱用治療市場規模 アルゼンチンの薬物乱用治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The substance abuse treatment market is expected to register a CAGR of 7.2% during the forecast period.
Due to the COVID-19 pandemic, government authorities across the world have taken the necessary steps to make substance abuse treatment accessible to patients. This can be attributed to the fact that the prognosis of patients’ co-occurring conditions, such as chronic obstructive pulmonary disease, cardiovascular disease, and other respiratory diseases, is worsened by COVID-19, negatively impacting the lives of substance-addicted and alcohol-addicted patients. For instance, an article titled “Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond,” published in November 2021, stated that federal and state governments implemented temporary strategies for providing access to opioid use disorder (OUD) treatment during the COVID-19 pandemic. The article also stated that all the states and Washington, DC had adopted at least one telehealth policy in order to improve access to OUD treatment for new patients. Thus, there has been an increase in demand for substance abuse treatment amid the ongoing COVID-19 pandemic.
Further, the factors that are driving the market growth include rising drug awareness campaigns and prevention programs and growth in the number of addictions among the population. The surge in drug awareness campaigns and associated prevention programs is one of the primary factors linked to the growth of the market studied. This includes rising patient awareness, a higher treatment-seeking rate with increased government intervention, and encouragement to curb substance abuse in several countries. For instance, in December 2021, the Indian government launched the “Drug-Free India” campaign and issued directions for curbing drug abuse in the Indian populace. Likewise, in October 2021, the Centers for Disease Control and Prevention (CDC) launched four complementary education campaigns intended to reach young adults ages 18–34 years aimed at preventing drug overdose deaths. The campaigns provide information about the prevalence and dangers of fentanyl, the risks and consequences of mixing drugs, the life-saving power of naloxone, and the importance of reducing the stigma around drug use to support treatment and recovery. Such campaigns and initiatives are increasing awareness regarding substance abuse treatment among the addicted population, thereby contributing to the market’s growth.
However, the reluctance of individuals to access treatment modalities, the discontinuation of behavioral therapies, and poor treatment compliance in some countries hinder the growth of the market studied.
Substance Abuse Treatment Market Trends
The Tobacco/Nicotine Addiction Treatment Segment is Expected to Dominate the Market
By treatment type, the tobacco/nicotine addiction treatment segment is anticipated to witness lucrative growth. Tobacco and its usage through consumption and smoking are harmful, as they kill half of its users globally, as stated by the World Health Organization. In July 2021, the same source stated that tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use, while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Moreover, the use of tobacco is greater in developing and underdeveloped countries, especially in the Pacific and East Asian countries. Such factors are anticipated to boost the growth of the segment in the developing as well as developed countries over the coming years.
Furthermore, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in December 2021, the NFL Biosciences launched the Phase II/III clinical trial to assess the efficacy and safety of its NFL-101 smoking cessation treatment. It is approved by the Human Research Ethics Committee (HREC) in Australia and by the French National Agency for the Safety of Medicines and Health Products (ANSM). Similarly, in September 2021, Mydecine Innovations Group launched a Phase 2/3 clinical trial for smoking cessation for its MYCO-001 compound, following up on its recent announcement of 5-year cooperation with Johns Hopkins University’s research institute. In this ground-breaking trial, Mydecine will collaborate with John Hopkins, and the trial will be a randomized, double-blind, placebo-controlled experiment to assess the efficacy of Mydecine’s MYCO-001 in the treatment of nicotine addiction.
Hence, all these factors are expected to help this market grow during the forecast period.
North America is Expected to Dominate the Market During the Forecast Period
Within North America, the United States is expected to dominate the market due to the increasing overuse of tobacco and an increasing number of government initiatives aimed at reducing substance abuse.
For instance, as per a December 2020 update by the Centers for Disease Control and Prevention (CDC), nearly 14 out of every 100 United States adults aged 18 years or older (14.0%) smoked cigarettes in 2019. As per the same source, an estimated 34.1 million adults in the United States currently smoke cigarettes, and more than 16 million Americans live with a smoking-related disease. Such a prevalent addiction population within the country will necessitate the demand for addiction treatments, in turn, driving the market growth in the United States.
Furthermore, various initiatives are being implemented by the United States government to monitor the symptoms and determine drug abuse among the American population. For instance, as per a February 2022 update, the United States government and the United Kingdom are administering Narcan, a brand name for the medicine naloxone, in 16 counties at no cost to help reduce overdose deaths. Such initiatives will further supplement the growth of substance abuse treatment within the country.
Additionally, the United States has an advanced healthcare system with one of the largest expenditures on healthcare. Its investment in research and development, along with measures to curb and eliminate substance abuse, is further aiding access to addiction treatments among Americans. As a result of these factors, a large population is able to get the required treatment it needs. For instance, as per a February 2022 update, Texas and some of its largest counties will receive USD 1.17 billion as an opioid relief fund as part of a nationwide settlement from three large pharmaceutical distribution companies. Moreover, in February 2022, the United States Department of Human Health and Services announced a USD 10 million Substance Abuse and Mental Health Services Administration (SAMHSA) grant program addressing the health needs of pregnant women and children affected by substance use. Such programs are anticipated to drive the demand for substance abuse treatment in the United States, thereby driving the market growth.
Thus, owing to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
Substance Abuse Treatment Market Competitor Analysis
The substance abuse treatment market is competitive and consists of a fewer number of major players. Market leaders with more funds for research and a better distribution system have established their position in the market. The major players in the market are Alkermes, Mallinckrodt, GSK, Cipla, and Idiviour, among other market players.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Drug Awareness Campaigns and Prevention Programs
4.2.2 High Number of Addicted Population
4.3 Market Restraints
4.3.1 Reluctance of Individuals for Accessing Treatment and Discontinuation of the Behavioral Therapies
4.3.2 Poor Treatment Compliance in Some Countries
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Treatment Type
5.1.1 Alcohol Addiction Treatment
5.1.2 Tobacco/Nicotine Addiction Treatment
5.1.3 Drug Abuse Treatment
5.1.4 Other Treatment Types
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other Distribution Channels
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alkermes PLC
6.1.2 Abbvie Inc.
6.1.3 Cipla Ltd
6.1.4 GlaxoSmithKline PLC
6.1.5 Mallinckrodt LLC
6.1.6 Indivior PLC
6.1.7 Pfizer Inc.
6.1.8 Sanofi SA
6.1.9 Teva Pharmaceutical Industries Ltd
6.1.10 Orexo AB
6.1.11 Apotex
6.1.12 BioCorRx Inc.
6.1.13 Opiant Pharmaceuticals Inc.
6.1.14 Purdue Pharma LP
6.1.15 Novartis AG (Sandoz)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
